Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse.  Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work with the NIF mouse, and comments on the positive results. You will find the full pressrelease here.